1. Home
  2. IMMX vs SRL Comparison

IMMX vs SRL Comparison

Compare IMMX & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMX
  • SRL
  • Stock Information
  • Founded
  • IMMX 2014
  • SRL 2017
  • Country
  • IMMX United States
  • SRL China
  • Employees
  • IMMX N/A
  • SRL N/A
  • Industry
  • IMMX Medicinal Chemicals and Botanical Products
  • SRL Professional Services
  • Sector
  • IMMX Health Care
  • SRL Consumer Discretionary
  • Exchange
  • IMMX Nasdaq
  • SRL Nasdaq
  • Market Cap
  • IMMX 82.6M
  • SRL 86.1M
  • IPO Year
  • IMMX 2021
  • SRL N/A
  • Fundamental
  • Price
  • IMMX $3.05
  • SRL $5.77
  • Analyst Decision
  • IMMX Strong Buy
  • SRL
  • Analyst Count
  • IMMX 1
  • SRL 0
  • Target Price
  • IMMX $8.00
  • SRL N/A
  • AVG Volume (30 Days)
  • IMMX 453.7K
  • SRL 9.1K
  • Earning Date
  • IMMX 11-11-2025
  • SRL 04-30-2025
  • Dividend Yield
  • IMMX N/A
  • SRL 18.37%
  • EPS Growth
  • IMMX N/A
  • SRL N/A
  • EPS
  • IMMX N/A
  • SRL N/A
  • Revenue
  • IMMX N/A
  • SRL $24,535,042.00
  • Revenue This Year
  • IMMX N/A
  • SRL N/A
  • Revenue Next Year
  • IMMX N/A
  • SRL N/A
  • P/E Ratio
  • IMMX N/A
  • SRL N/A
  • Revenue Growth
  • IMMX N/A
  • SRL N/A
  • 52 Week Low
  • IMMX $1.34
  • SRL $5.13
  • 52 Week High
  • IMMX $3.20
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • IMMX 77.89
  • SRL 51.79
  • Support Level
  • IMMX $2.31
  • SRL $5.65
  • Resistance Level
  • IMMX $2.82
  • SRL $6.00
  • Average True Range (ATR)
  • IMMX 0.25
  • SRL 0.24
  • MACD
  • IMMX 0.08
  • SRL -0.02
  • Stochastic Oscillator
  • IMMX 95.41
  • SRL 48.06

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: